Rejected from Nature Chemistry? Where to Submit Next

The useful question is not "which chemistry journal is easier?" It is "what did Nature Chemistry not believe about this manuscript?"

If the editor did not believe the central advance was chemistry-first, the next journal should probably be materials, catalysis, energy, chemical biology, nanoscience, or application-focused. If the editor believed the chemistry mattered but the breadth was too narrow, JACS, Angewandte Chemie, Chem, or Chemical Science may be better. If reviewers questioned characterization, mechanism, benchmarking, data availability, reproducibility, methods detail, or Supplementary Information, those problems travel with the paper.

Use the decision letter to classify the failure:

Nature Chemistry is not simply the highest-prestige version of a specialist chemistry journal. The official aims and scope are broad: the paper can come from many subfields, but the central theme and major advance must fall within chemistry and matter to a broad chemistry readership.

That makes the rejection diagnostically useful. It often means one of three things:

• The chemistry is not the protagonist. The paper may be impressive because of a device, material, biological assay, sustainability application, or performance result, while the chemical principle is secondary.
• The advance is real but too local. A new ligand, catalyst, synthesis route, supramolecular motif, polymer, surface, computation, or mechanism may be strong for specialists but not obviously important across chemistry.
• The evidence package does not match the claim. Nature Portfolio policies emphasize methods, data, code, protocols, materials availability, and reproducibility. If the claim depends on characterization, computation, reaction scope, mechanism, or benchmark data that reviewers cannot audit, the next journal will see the same weakness.

This is why the next submission should be routed by manuscript phenotype, not by impact-factor adjacency.

This page was researched from current Nature Chemistry aims and scope, submission guidelines, content-type guidance, preparing-your-material instructions, Nature Portfolio reporting and data-availability policies, and Manusights' existing Nature Chemistry content cluster. The official materials support three practical routing constraints: the work needs chemistry-wide importance, the cover letter must explain fit for a diverse Nature Chemistry readership, and the manuscript package must allow a fellow expert to interpret and replicate the work.

In our analysis of the post-rejection routing job, the non-obvious question is not whether JACS or Angewandte Chemie is "next." It is which manuscript component created the rejection signal: title promise, abstract claim, first figure, mechanism, characterization, benchmark table, reaction scope, computation, methods, data availability, cover letter, or Supplementary Information.

The specific rejection patterns below are written as a diagnostic, not as a generic journal list. We see authors lose time when they interpret a Nature Chemistry rejection as a prestige problem, but the paper actually has a chemistry-protagonist, breadth, evidence, or audience problem. In practice, the best next journal is the one where the manuscript's evidence can support its claim without forcing a Nature Chemistry-level cross-subfield argument that the data cannot carry.

Rebuild for Nature Chemistry only when the manuscript still has a broad chemistry-first claim and the rejection exposed a repairable weakness. This is most plausible after a desk rejection that points to presentation or fit, or a reviewer rejection where the missing evidence is achievable.

Good reasons to rebuild:

• The central result changes chemical understanding across more than one immediate subfield.
• The rejection questioned framing, abstract logic, first-figure order, cover-letter breadth, benchmarking, characterization, or Supplementary Information rather than the underlying result.
• Missing characterization, control experiments, kinetic evidence, substrate scope, computational validation, materials availability, data statement, or protocol detail can be added quickly.
• The strongest chemistry principle was hidden behind application data, device performance, biological context, materials optimization, or sustainability framing.

Bad reasons to rebuild:

• You only want to stay near the Nature Portfolio brand.
• The paper is excellent but clearly specialist.
• The application is stronger than the chemistry principle.
• The core limitation requires a new mechanism study, new substrate set, new characterization campaign, new computation, or different experimental design.

If you rebuild, make the correction visible early. The title, 150-word abstract, first display item, and cover letter should all make the chemistry advance unavoidable before the application or specialist detail takes over.

JACS is often the strongest next route when the paper remains broad chemistry but does not need Nature Chemistry's editorial framing. If the story has clear mechanism, characterization, scope, controls, and chemical consequence, JACS can be a better fit than forcing a Nature Portfolio pitch.

Angewandte Chemie can be better when the manuscript is concise, high-impact, and cross-subfield but does not require a long, highly contextual Nature Chemistry article. It rewards chemistry novelty that a broad chemistry audience can understand quickly.

Chem or ACS Central Science can be better when the manuscript has broad chemical science value but also benefits from a more general-science, mechanistic, or interdisciplinary framing.

Choose these routes when the manuscript can answer:

• What chemical principle, transformation, structure, mechanism, reactivity, design rule, or measurement advance is new?
• Which evidence proves that advance rather than merely supporting an application?
• Would chemists outside the immediate subfield care before they see the performance result?
• Does the paper need Nature Chemistry's audience, or a strong chemistry flagship audience?

If the answer is mostly "the material/device/application works well," retarget to the application-facing venue.

Many Nature Chemistry rejections are strong papers in the wrong lane.

Move toward Nature Catalysis, ACS Catalysis, Journal of Catalysis, or Applied Catalysis B when the real contribution is catalytic mechanism, selectivity, stability, conversion, energy, environment, or process performance. Move toward Nature Materials, Advanced Materials, Chemistry of Materials, or ACS Applied Materials and Interfaces when the material or interface is the protagonist. Move toward Nature Chemical Biology, ACS Chemical Biology, or a biological chemistry journal when the work is chemistry-enabled biology.

Move toward physical, analytical, inorganic, organic, supramolecular, polymer, computational, or surface-chemistry journals when the paper's best readers are specialists. A specialist venue is not a failure if it gives reviewers the right context and avoids broad overclaiming.

The rewrite should reduce Nature Chemistry-specific breadth language. Do not pretend every strong chemistry result needs a chemistry-wide claim. Make the action specific: which chemist can use the mechanism, method, molecule, material, catalyst, spectrum, computation, design rule, or benchmark?

In our pre-submission and post-decision review work with manuscripts aimed at Nature Chemistry, the highest-value repairs are usually not language edits. They are chemistry-protagonist and evidence-package decisions tied to concrete components: title, 150-word abstract, first display item, mechanism figure, characterization table, benchmark set, reaction or material scope, computation, methods, data-availability statement, cover letter, Supplementary Information, and limitations.

Three specific rejection patterns are especially common.

The application-over-chemistry gap. The manuscript opens with a battery, device, sensor, therapeutic, sustainability, materials, or biological outcome, but the chemistry principle arrives late. Nature Chemistry is risky when the strongest result is an application and the chemistry is only the enabling platform. The repair is to make the chemical advance the protagonist, or move to the application-facing journal that will value the outcome directly.

The specialist-depth gap. The paper is strong but speaks mainly to one subfield. A new ligand, synthesis, catalyst, polymer, surface, computational workflow, supramolecular assembly, or characterization method may be meaningful, but the abstract and first figure do not show why chemists outside that subfield should care. The repair is either to expose the cross-subfield principle or choose a specialist venue.

The auditability gap. The claim depends on characterization, mechanism, scope, spectra, kinetics, computation, structures, stability, materials, data, code, or protocols, but the proof is hard to inspect. Nature Portfolio policies make reproducibility and availability part of the publication standard. The repair is to make the evidence trail easy for reviewers to audit before resubmission.

For Nature Chemistry specifically, we check whether the title, abstract, first display item, cover letter, Supplementary Information, and data statement all make the same chemistry-first promise. If any one of those components points to a more specialist, materials, catalysis, energy, biology, or methods journal, the resubmission should follow that signal instead of forcing the paper back into a Nature Chemistry story.

The practical lesson is direct: after Nature Chemistry rejection, the manuscript should either become a clearer chemistry-wide advance or a more honest paper for the audience that can use the evidence you actually have. The worst option is a cosmetic resubmission that preserves the same unsupported breadth claim.